Cu entuziasm și profesionalism, Dr. Dan CĂLUGĂRU a format o echipă bine pregătită, care având la dispoziție tehnică medicală performantă, ajută la rezolvarea problemelor oftalmologice, punând întotdeauna accent pe confortul și siguranța pacienților, oferind servicii oftamologice complete la standarde înalte de calitate, atât prin experiența profesională cât și ca nivel al dotării cu aparatură. Echipa beneficiază de suportul și experiența Prof. Univ. Dr. Mihai Călugăru.
Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: results from real-life setting
October, 2021, Vol. 11, Issue, 10, pp. 51293-51294
Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration
September 2021, Vol. 11, Issue 09, pp. 50295-50296
Efficacy and safety of intravitreal aflibercept treat-and-extent for macular edema in central retinal vein occlusion: The Centera Study
July 2021, Vol. 11, Issue 07, pp. 48674-48675
Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes
June 2021, Vol. 11, Issue 06, pp. 47588-47589
Intraocular pressure modifications in patients with acute central/hemicentral retinal vein occlusions
June 2021, Vol. 14, Issue 6, pp.931-935
Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the Latar study
April 2021, Vol. 11, Issue 04, pp.46571-46572
Bilateral central retinal vein occlusion in a 40-year-old man with severe coronavirus disease 2019 (covid-19) pneumonia
March 2021, Vol. 11, Issue 03, pp.45563-45564
Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-vascular endothelial growth factor therapy. prognosis and predictive factors
April 2021, Vol. 11, Issue 04, pp.46111-46112
One-year real-life results on effect of inravitreal aflibercept in patients with diabetic macular edema switched from ranibizumab
March 2021, Vol. 11, Issue 03, pp.45047-45048
The impact of race on short term treatment response to bevacizumab in diabetic macular edema
February 2021, Vol. 13, Issue 02, pp.16147-16148
Spectral-domain oct analysis of risk factors for macular atrophy development in the harbor study for neovascular age-related macular degeneration
December 2020, Vol. 12, Issue 12, pp.15081-15082
Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration. data from the fight retinal blindness registry
October 2020, Volume 10, Issue 10, pp. 41553-41554
Comment on “Anatomical and functional changes after dexamethasone implant and ranibizumab in diabetic macular edema: a retrospective cohort study”
October 2020, Volume 13, Issue 10, 1678-1680
Ranibizumab or aflibercept for diabetic macular edema. comparison of 1-year outcomes from the fight retinal blindness registry
September 2020, Vol. 10, Issue 09, pp. 40816-40817
Switching from ranibizumab and aflibercept to bevacizumab therapy in neovascular age-related macular degeneration patients
September 2020, Volume 30, Issue 5, p. NP1-NP2
Correspondence
September 2020, Vol. 40, Issue 9, p. e49-e51
Clinical characteristics and outcome of posterior cystoid macular degeneration in chornic central serous chorioretinopathy
August 2020, Vol. 10, Issue 08, pp. 39687-39688
Correspondence
August 2020, Volume 40, Issue 8, p. e39-e41
Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion
July 2020, Vol. 10, Issue 07, pp. 38629-38630
Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy
July 2020, Vol. 10, Issue 07, pp. 37858-37859
Response of neovascular central serous chorioretinopathy to an extended upload of anti-vegf agents
June 2020, Vol. 10, Issue 06, pp. 36286-36288
Hawk and Harrier: phase 3, multicenter, randomizaed, double-masked trials of brolucizumab for neovascular age-related macular degeneration
April 2020, Vol. 10, Issue 04, pp. 35070-35071
Bun venit!
În clinica noastră se tratează peste 3000 de pacienți anual, număr în permanentă creștere, având în vedere progresul științific și tehnic de care echipa Dr. Călugăru este mereu preocupată.
Echipamentele noaste sunt furnizate de către producători consacrați în domeniu: Alcon (S.U.A), Bausch & Lomb (SUA), Blanco (Germania), Brumaba (Germania), Carl Zeiss Meditec (Germania), Spacelabs (S.U.A), Getinge (Suedia), Tomey (Japonia), Melag (Germania), Nidek (Japonia), Briot (Belgia).
Pentru operațiile de reducere a dioptriilor cu laser excimer (Lasek, Prk) nu este nevoie de analize. Pentru toate celelalte intervenții chirurgicale analizele sunt obligatorii.
Analizele necesare pentru operație:
- Hemoleucograma
- Coagulograma
- Glicemie
- Uree
- VSH
- AST
- ALT
- Bilirubina totală
- HVB
- HVC
- HIV
- Consult cardiologic
- EKG
Pentru a reuși vindecarea unui număr cât mai mare de pacienți echipa Dr. Călugăru colaborează cu mai mulți medici specializați în oftalmologie, opticieni și optometriști, cât și cu medicii de familie din zonele învecinate.